Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference newsletter


  Breast Cancer

  Free Subscription


26.10.2020

1 AJR Am J Roentgenol
2 Am J Surg Pathol
1 Ann Surg
10 Ann Surg Oncol
3 BMC Cancer
3 Br J Cancer
2 Breast Cancer
3 Breast Cancer Res
11 Breast Cancer Res Treat
8 Breast J
3 Cancer
1 Cancer Chemother Pharmacol
2 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
8 Cancer Res
2 Cell
2 Clin Cancer Res
1 Clin Exp Metastasis
1 Eur J Surg Oncol
2 Exp Cell Res
2 Int J Cancer
1 Int J Oncol
1 J Biol Chem
3 J Clin Oncol
1 J Natl Cancer Inst
1 Nat Rev Clin Oncol
1 Nature
9 NPJ Breast Cancer
2 Oncogene
1 Oncology (Williston Park)
9 PLoS One
1 Proc Natl Acad Sci U S A
2 Radiology
1 Radiother Oncol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MUZAHIR S
    Molecular Breast Cancer Imaging in the Era of Precision Medicine.
    AJR Am J Roentgenol. 2020 Oct 21:1-8. doi: 10.2214/AJR.20.22883.
    PubMed         Abstract available


    Am J Surg Pathol

  2. NORKOWSKI E, Masliah-Planchon J, Le Guellec S, Trassard M, et al
    Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
    Am J Surg Pathol. 2020;44:1266-1273.
    PubMed         Abstract available

  3. ZHONG E, Solomon JP, Cheng E, Baum J, et al
    Apocrine Variant of Pleomorphic Lobular Carcinoma In Situ: Further Clinical, Histopathologic, Immunohistochemical, and Molecular Characterization of an Emerging Entity.
    Am J Surg Pathol. 2020;44:1092-1103.
    PubMed         Abstract available


    Ann Surg

  4. MARTELLI G, Barretta F, Miceli R, Folli S, et al
    Sentinel Node Biopsy alone or with Axillary Dissection in Breast Cancer Patients after Primary Chemotherapy: Long-term Results of a Prospective Interventional Study.
    Ann Surg. 2020 Oct 15. doi: 10.1097/SLA.0000000000004562.
    PubMed         Abstract available


    Ann Surg Oncol

  5. ANGARITA S, Ye L, Runger D, Hadaya J, et al
    Assessing the Burden of Nodal Disease for Breast Cancer Patients with Clinically Positive Nodes: Hope for More Limited Axillary Surgery.
    Ann Surg Oncol. 2020 Oct 21. pii: 10.1245/s10434-020-09228.
    PubMed         Abstract available

  6. OZKURT E, Wong S, Rhei E, Golshan M, et al
    Omission of Surgical Axillary Lymph Node Staging in Patients with Tubular Breast Cancer.
    Ann Surg Oncol. 2020 Oct 19. pii: 10.1245/s10434-020-09223.
    PubMed         Abstract available

  7. ZHANG J, Xiao L, Pu S, Liu Y, et al
    Can We Reliably Identify the Pathological Outcomes of Neoadjuvant Chemotherapy in Patients with Breast Cancer? Development and Validation of a Logistic Regression Nomogram Based on Preoperative Factors.
    Ann Surg Oncol. 2020 Oct 23. pii: 10.1245/s10434-020-09214.
    PubMed         Abstract available

  8. NIZIC-KOS T, Besic N
    ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations.
    Ann Surg Oncol. 2020 Oct 18. pii: 10.1245/s10434-020-09196.
    PubMed        

  9. HELLER DR, Friedrich AU, Killelea BK
    Genetic Testing for Breast Cancer Patients: Is Everyone Who Needs a Test Getting a Test?
    Ann Surg Oncol. 2020 Oct 15. pii: 10.1245/s10434-020-09180.
    PubMed        

  10. BLOOM JA, Asban A, Tian T, Sekigami Y, et al
    A Cost-Utility Analysis Comparing Immediate Oncoplastic Surgery with Delayed Oncoplastic Surgery in Smoking Breast Cancer Patients.
    Ann Surg Oncol. 2020 Oct 13. pii: 10.1245/s10434-020-09220.
    PubMed         Abstract available

  11. BATENI SB, Perry LM, Zhao X, Arora M, et al
    The Role of Radiation Therapy in Addition to Lumpectomy and Hormone Therapy in Men 70 Years of Age and Older with Early Breast Cancer: A NCDB Analysis.
    Ann Surg Oncol. 2020 Oct 22. pii: 10.1245/s10434-020-09242.
    PubMed         Abstract available

  12. WONG SM, Basik M, Florianova L, Margolese R, et al
    Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer.
    Ann Surg Oncol. 2020 Oct 23. pii: 10.1245/s10434-020-09211.
    PubMed         Abstract available

  13. KUERER HM, Blair SL
    The Virtual Scientific Sessions from the American Society of Breast Surgeons During the COVID-19 Pandemic.
    Ann Surg Oncol. 2020;27:4585-4587.
    PubMed        

  14. OFFODILE AC 2ND, Asaad M, Boukovalas S, Bailey C, et al
    Financial Toxicity Following Surgical Treatment for Breast Cancer: A Cross-sectional Pilot Study.
    Ann Surg Oncol. 2020 Oct 13. pii: 10.1245/s10434-020-09216.
    PubMed         Abstract available


    BMC Cancer

  15. MA T, Liu H, Liu Y, Liu T, et al
    USP6NL mediated by LINC00689/miR-142-3p promotes the development of triple-negative breast cancer.
    BMC Cancer. 2020;20:998.
    PubMed         Abstract available

  16. AGBEKO AE, Arthur J, Bayuo J, Kaburi BB, et al
    Seeking healthcare at their 'right' time; the iterative decision process for women with breast cancer.
    BMC Cancer. 2020;20:1011.
    PubMed         Abstract available

  17. LEI YY, Ho SC, Kwok C, Cheng A, et al
    Longitudinal changes in sports activity from pre-diagnosis to first five years post-diagnosis: a prospective Chinese breast cancer cohort study.
    BMC Cancer. 2020;20:1013.
    PubMed         Abstract available


    Br J Cancer

  18. EVANS DG, Edwards M, Duffy SW, Tischkowitz M, et al
    Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
    Br J Cancer. 2020;122:329-332.
    PubMed         Abstract available

  19. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    PubMed         Abstract available

  20. VISSIO E, Metovic J, Osella-Abate S, Bertero L, et al
    Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling.
    Br J Cancer. 2020;122:382-387.
    PubMed         Abstract available


    Breast Cancer

  21. MASUDA N, Mukai H, Inoue K, Rai Y, et al
    Analysis of subsequent therapy in Japanese patients with hormone receptorpositive/human epidermal growth factor receptor 2negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
    Breast Cancer. 2020 Oct 21. pii: 10.1007/s12282-020-01162.
    PubMed         Abstract available

  22. LIANG H, Zhou G, Lv L, Lu J, et al
    KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
    Breast Cancer. 2020 Oct 16. pii: 10.1007/s12282-020-01170.
    PubMed         Abstract available


    Breast Cancer Res

  23. FALSTIE-JENSEN AM, Esen BO, Kjaersgaard A, Lorenzen EL, et al
    Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study.
    Breast Cancer Res. 2020;22:106.
    PubMed         Abstract available

  24. DRUCKER A, Yoo BH, Khan IA, Choi D, et al
    Correction to: Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity.
    Breast Cancer Res. 2020;22:110.
    PubMed         Abstract available

  25. MONSON KR, Goldberg M, Wu HC, Santella RM, et al
    Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    Breast Cancer Res. 2020;22:109.
    PubMed         Abstract available


    Breast Cancer Res Treat

  26. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 22. pii: 10.1007/s10549-020-05976.
    PubMed         Abstract available

  27. KARIRI YA, Alsaleem M, Joseph C, Alsaeed S, et al
    The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05955.
    PubMed         Abstract available

  28. KUMAR R, Kuligina E, Sokolenko A, Siddiqui Q, et al
    Genetic ablation of pregnancy zone protein promotes breast cancer progression by activating TGF-beta/SMAD signaling.
    Breast Cancer Res Treat. 2020 Oct 15. pii: 10.1007/s10549-020-05958.
    PubMed         Abstract available

  29. WU ZY, Kim N, Ko B
    Tumor localization for breast cancer patients receiving neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05950.
    PubMed        

  30. ZHOU M, Venkata PP, Viswanadhapalli S, Palacios B, et al
    KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 14. pii: 10.1007/s10549-020-05963.
    PubMed         Abstract available

  31. BREZDEN-MASLEY C, Fathers KE, Coombes ME, Pourmirza B, et al
    A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05960.
    PubMed         Abstract available

  32. LU YC, Huang DW, Chen PT, Tsai CF, et al
    Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study.
    Breast Cancer Res Treat. 2020 Oct 16. pii: 10.1007/s10549-020-05969.
    PubMed         Abstract available

  33. SIM EJ, Ko KP, Ahn C, Park SM, et al
    Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05875.
    PubMed         Abstract available

  34. GARCIA-TEJEDOR A, Fernandez-Gonzalez S, Ortega R, Gil-Gil M, et al
    Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
    Breast Cancer Res Treat. 2020 Oct 17. pii: 10.1007/s10549-020-05970.
    PubMed         Abstract available

  35. WEISER R, Haque W, Polychronopoulou E, Hatch SS, et al
    The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis.
    Breast Cancer Res Treat. 2020 Oct 18. pii: 10.1007/s10549-020-05971.
    PubMed         Abstract available

  36. SIMONS JM, Jacobs JG, Roijers JP, Beek MA, et al
    Disease-free and overall survival after neoadjuvant chemotherapy in breast cancer: breast-conserving surgery compared to mastectomy in a large single-centre cohort study.
    Breast Cancer Res Treat. 2020 Oct 19. pii: 10.1007/s10549-020-05966.
    PubMed         Abstract available


    Breast J

  37. SALEMIS NS, Nakos G, Stavrinou N, Spiliopoulos K, et al
    Metastatic brachial plexopathy as the initial manifestation of breast cancer.
    Breast J. 2020 Oct 21. doi: 10.1111/tbj.14096.
    PubMed        

  38. QI WX, Cao L, Xu C, Zhao S, et al
    Dual HER2 blockade therapy increases the risk of developing cardiac toxicities in HER2-positive breast cancer: An up-to-date comprehensive meta-analysis.
    Breast J. 2020 Oct 21. doi: 10.1111/tbj.14098.
    PubMed        

  39. VIEIRA RADC, Navarro de Oliveira LC, Martins RM, Falcao-Junior PC, et al
    Schwannoma associated with breast cancer mimicking axillary metastasis.
    Breast J. 2020 Oct 19. doi: 10.1111/tbj.14090.
    PubMed        

  40. WHITLOCK AE, Allar BG, James T
    Pausing for the pandemic? The impact of deferring breast cancer surgery.
    Breast J. 2020 Oct 23. doi: 10.1111/tbj.14084.
    PubMed        

  41. ATALLAH D, Moubarak M, Arab W, El Kassis N, et al
    MRI-based predictive factors of axillary lymph node status in breast cancer.
    Breast J. 2020 Oct 18. doi: 10.1111/tbj.14089.
    PubMed         Abstract available

  42. BAYRAMGIL A, Bilici A, Hamdard J, Acikgoz O, et al
    Triple-negative breast cancer presented with metastasis to the heart as first sign of recurrence.
    Breast J. 2020 Oct 18. doi: 10.1111/tbj.14091.
    PubMed        

  43. BERRAZAGA Y, Yahyaoui Y, Hamdi A, Letaief F, et al
    Breast cancer T1 in an emerging country: 325 Tunisian cases.
    Breast J. 2020 Oct 13. doi: 10.1111/tbj.14083.
    PubMed        

  44. NGO C, Sharifzadehgan S, Lecurieux-Lafayette C, Belhouari H, et al
    Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity-The FLUOBREAST trial.
    Breast J. 2020 Oct 22. doi: 10.1111/tbj.14100.
    PubMed         Abstract available


    Cancer

  45. RAMIREZ AG, Choi BY, Munoz E, Perez A, et al
    Assessing the effect of patient navigator assistance for psychosocial support services on health-related quality of life in a randomized clinical trial in Latino breast, prostate, and colorectal cancer survivors.
    Cancer. 2019 Nov 19. doi: 10.1002/cncr.32626.
    PubMed         Abstract available

  46. NAUGHTON MJ, Liu H, Seisler DK, Le-Rademacher J, et al
    Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients.
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33184.
    PubMed         Abstract available

  47. PASKETT ED, Le-Rademacher J, Oliveri JM, Liu H, et al
    A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).
    Cancer. 2020 Oct 20. doi: 10.1002/cncr.33183.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  48. ZHANG Z, Zhang L, Yu G, Sun Z, et al
    Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2020 Oct 17. pii: 10.1007/s00280-020-04168.
    PubMed         Abstract available


    Cancer Epidemiol Biomarkers Prev

  49. PATULEIA SIS, Hagenaars SC, Moelans CB, Ausems MGEM, et al
    Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2020 Oct 20. pii: 1055-9965.EPI-20-0770.
    PubMed         Abstract available

  50. MCDOUGALL JA, Cook LS, Tang MC, Thompson B, et al
    Determinants of Guideline-Discordant Breast Cancer Care.
    Cancer Epidemiol Biomarkers Prev. 2020 Oct 22. pii: 1055-9965.EPI-20-0985.
    PubMed         Abstract available


    Cancer Lett

  51. BAI X, Ni J, Beretov J, Graham P, et al
    Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Cancer Lett. 2020;497:100-111.
    PubMed         Abstract available

  52. ZHANG N, Sun P, Xu Y, Li H, et al
    The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERalpha to inhibit the growth of breast cancer induced by oestrogen.
    Cancer Lett. 2020 Oct 15. pii: S0304-3835(20)30545.
    PubMed         Abstract available


    Cancer Res

  53. QIAO X, Liu Y, Prada ML, Mohan AK, et al
    UBR5 Is Coamplified with MYC in Breast Tumors and Encodes an Ubiquitin Ligase That Limits MYC-Dependent Apoptosis.
    Cancer Res. 2020;80:1414-1427.
    PubMed         Abstract available

  54. MEULEMANS L, Mesman RLS, Caputo SM, Krieger S, et al
    Skipping Nonsense to Maintain Function: The Paradigm of BRCA2 Exon 12.
    Cancer Res. 2020;80:1374-1386.
    PubMed         Abstract available

  55. ROBERTS MS, Sahni JM, Schrock MS, Piemonte KM, et al
    LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
    Cancer Res. 2020;80:1693-1706.
    PubMed         Abstract available

  56. SCHIPPER K, Drenth AP, van der Burg E, Cornelissen S, et al
    Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.
    Cancer Res. 2020;80:1486-1497.
    PubMed         Abstract available

  57. VANNA R, Morasso C, Marcinno B, Piccotti F, et al
    Raman Spectroscopy Reveals That Biochemical Composition of Breast Microcalcifications Correlates with Histopathologic Features.
    Cancer Res. 2020;80:1762-1772.
    PubMed         Abstract available

  58. HOLOWKO N, Eriksson M, Kuja-Halkola R, Azam S, et al
    Heritability of Mammographic Breast Density, Density Change, Microcalcifications, and Masses.
    Cancer Res. 2020;80:1590-1600.
    PubMed         Abstract available

  59. KENNEDY KM, Zilkens R, Allen WM, Foo KY, et al
    Diagnostic Accuracy of Quantitative Micro-Elastography for Margin Assessment in Breast-Conserving Surgery.
    Cancer Res. 2020;80:1773-1783.
    PubMed         Abstract available

  60. SMALLEY M, Natarajan SK, Mondal J, Goldman D, et al
    Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer.
    Cancer Res. 2020 Oct 19. pii: 0008-5472.CAN-19-4036.
    PubMed         Abstract available


    Cell

  61. PAINTER C
    Reaching for the Brass Ring.
    Cell. 2020;181:8-14.
    PubMed        

  62. LU Y, Zhao Q, Liao JY, Song E, et al
    Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity.
    Cell. 2020;180:1081-1097.
    PubMed         Abstract available


    Clin Cancer Res

  63. SHAH M, Wedam S, Cheng J, Fiero MH, et al
    FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Oct 14. pii: 1078-0432.CCR-20-2701.
    PubMed         Abstract available

  64. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed         Abstract available


    Clin Exp Metastasis

  65. PARK SB, Hwang KT, Chung CK, Roy D, et al
    Causal Bayesian gene networks associated with bone, brain and lung metastasis of breast cancer.
    Clin Exp Metastasis. 2020 Oct 20. pii: 10.1007/s10585-020-10060.
    PubMed         Abstract available


    Eur J Surg Oncol

  66. KAHLER-RIBEIRO-FONTANA S, Pagan E, Magnoni F, Vicini E, et al
    Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up.
    Eur J Surg Oncol. 2020 Oct 15. pii: S0748-7983(20)30846.
    PubMed         Abstract available


    Exp Cell Res

  67. WU G, Zhou H, Li D, Zhi Y, et al
    LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis.
    Exp Cell Res. 2020;396:112331.
    PubMed         Abstract available

  68. ZHANG W, Veisaga ML, Barbieri MA
    Role of RIN1 on telomerase activity driven by EGF-Ras mediated signaling in breast cancer.
    Exp Cell Res. 2020;396:112318.
    PubMed         Abstract available


    Int J Cancer

  69. ZUPUNSKI L, Yaumenenka A, Ryzhov A, Veyalkin I, et al
    Breast cancer incidence in the regions of Belarus and Ukraine most contaminated by the Chernobyl accident: 1978-2016.
    Int J Cancer. 2020 Oct 16. doi: 10.1002/ijc.33346.
    PubMed         Abstract available

  70. ZHANG Y, Wang P, Li X, Ning S, et al
    GABC: A Comprehensive Resource and Genome Atlas for Breast Cancer.
    Int J Cancer. 2020 Oct 16. doi: 10.1002/ijc.33347.
    PubMed         Abstract available


    Int J Oncol

  71. GALLARDO M, Kemmerling U, Aguayo F, Bleak TC, et al
    Curcumin rescues breast cells from epithelialmesenchymal transition and invasion induced by antimiR34a.
    Int J Oncol. 2020;56:480-493.
    PubMed         Abstract available


    J Biol Chem

  72. MCDONALD IM, Grant GD, East MP, Gilbert TSK, et al
    Mass spectrometry-based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells.
    J Biol Chem. 2020;295:2359-2374.
    PubMed         Abstract available


    J Clin Oncol

  73. DENDULURI N, Somerfield MR, Chavez-MacGregor M, Comander AH, et al
    Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
    J Clin Oncol. 2020 Oct 20:JCO2002510. doi: 10.1200/JCO.20.02510.
    PubMed         Abstract available

  74. FERNANDEZ-MARTINEZ A, Krop IE, Hillman DW, Polley MY, et al
    Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
    J Clin Oncol. 2020 Oct 23:JCO2001276. doi: 10.1200/JCO.20.01276.
    PubMed         Abstract available

  75. MULDER RL, Hudson MM, Bhatia S, Landier W, et al
    Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group.
    J Clin Oncol. 2020 Sep 29:JCO2000562. doi: 10.1200/JCO.20.00562.
    PubMed         Abstract available


    J Natl Cancer Inst

  76. SCHOORMANS D
    RE: Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Oct 15. pii: 5924374. doi: 10.1093.
    PubMed        


    Nat Rev Clin Oncol

  77. SASIENI PD, Sawyer EJ
    Intraoperative radiotherapy for early breast cancer - insufficient evidence to change practice.
    Nat Rev Clin Oncol. 2020 Oct 21. pii: 10.1038/s41571-020-00444.
    PubMed        


    Nature

  78. MCKINNEY SM, Sieniek M, Godbole V, Godwin J, et al
    Addendum: International evaluation of an AI system for breast cancer screening.
    Nature. 2020;586:E19.
    PubMed        


    NPJ Breast Cancer

  79. CAO Y, Baumgartner KB, Visvanathan K, Boone SD, et al
    Ethnic and biological differences in the association between physical activity and survival after breast cancer.
    NPJ Breast Cancer. 2020;6:51.
    PubMed         Abstract available

  80. JINDAL S, Narasimhan J, Borges VF, Schedin P, et al
    Characterization of weaning-induced breast involution in women: implications for young women's breast cancer.
    NPJ Breast Cancer. 2020;6:55.
    PubMed         Abstract available

  81. MARRA A, Trapani D, Viale G, Criscitiello C, et al
    Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies.
    NPJ Breast Cancer. 2020;6:54.
    PubMed         Abstract available

  82. PAREJA F, Ferrando L, Lee SSK, Beca F, et al
    The genomic landscape of metastatic histologic special types of invasive breast cancer.
    NPJ Breast Cancer. 2020;6:53.
    PubMed         Abstract available

  83. ZENG Z, Amin A, Roy A, Pulliam NE, et al
    Preoperative magnetic resonance imaging use and oncologic outcomes in premenopausal breast cancer patients.
    NPJ Breast Cancer. 2020;6:49.
    PubMed         Abstract available

  84. WOLF DM, Yau C, Wulfkuhle J, Brown-Swigart L, et al
    Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
    NPJ Breast Cancer. 2020;6:48.
    PubMed         Abstract available

  85. MICHMERHUIZEN AR, Spratt DE, Pierce LJ, Speers CW, et al
    ARe we there yet? Understanding androgen receptor signaling in breast cancer.
    NPJ Breast Cancer. 2020;6:47.
    PubMed         Abstract available

  86. VILLARREAL-GARZA C, Ferrigno AS, De la Garza-Ramos C, Barragan-Carrillo R, et al
    Clinical utility of genomic signatures in young breast cancer patients: a systematic review.
    NPJ Breast Cancer. 2020;6:46.
    PubMed         Abstract available

  87. BORGES VF, Hu J, Young C, Maggard J, et al
    Semaphorin 7a is a biomarker for recurrence in postpartum breast cancer.
    NPJ Breast Cancer. 2020;6:56.
    PubMed         Abstract available


    Oncogene

  88. LI Y, Li L, Qin J, Wu J, et al
    OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta1 autocrine to promote EMT and metastasis in breast cancer.
    Oncogene. 2020 Oct 13. pii: 10.1038/s41388-020-01499.
    PubMed         Abstract available

  89. ZHENG X, Lu S, He Z, Huang H, et al
    MCU-dependent negative sorting of miR-4488 to extracellular vesicles enhances angiogenesis and promotes breast cancer metastatic colonization.
    Oncogene. 2020 Oct 16. pii: 10.1038/s41388-020-01514.
    PubMed         Abstract available


    Oncology (Williston Park)

  90. WEISS A, Mittendorf EA, King TA
    Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy.
    Oncology (Williston Park). 2020;34:397-404.
    PubMed         Abstract available


    PLoS One

  91. SHARMA D, Cartar H, Law N, Giles A, et al
    Optimization of microbubble enhancement of hyperthermia for cancer therapy in an in vivo breast tumour model.
    PLoS One. 2020;15:e0237372.
    PubMed         Abstract available

  92. ZHANG C, Zhao J, Niu J, Li D, et al
    New convolutional neural network model for screening and diagnosis of mammograms.
    PLoS One. 2020;15:e0237674.
    PubMed         Abstract available

  93. CHA YJ, Koo JS
    Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.
    PLoS One. 2020;15:e0238466.
    PubMed         Abstract available

  94. YEASMEEN T, Kelaher M, Brotherton JML, Malloy MJ, et al
    Understanding the participation of breast screening among women born in predominantly Muslim countries living in Victoria, Australia from record-linkage data.
    PLoS One. 2020;15:e0237341.
    PubMed         Abstract available

  95. MOSAYEBI A, Mojaradi B, Bonyadi Naeini A, Khodadad Hosseini SH, et al
    Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer.
    PLoS One. 2020;15:e0237658.
    PubMed         Abstract available


  96. Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.
    PLoS One. 2020;15:e0241089.
    PubMed         Abstract available

  97. RODRIGUEZ NM, Casanova F, Pages G, Claure L, et al
    Community-based participatory design of a community health worker breast cancer training intervention for South Florida Latinx farmworkers.
    PLoS One. 2020;15:e0240827.
    PubMed         Abstract available

  98. SONG JH, Eum DY, Park SY, Jin YH, et al
    Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells.
    PLoS One. 2020;15:e0240533.
    PubMed         Abstract available

  99. PARK SH, Jeong YM, Lee HY, Kim EY, et al
    Opportunistic use of chest CT for screening osteoporosis and predicting the risk of incidental fracture in breast cancer patients: A retrospective longitudinal study.
    PLoS One. 2020;15:e0240084.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  100. YANG PB, Hou PP, Liu FY, Hong WB, et al
    Blocking PPARgamma interaction facilitates Nur77 interdiction of fatty acid uptake and suppresses breast cancer progression.
    Proc Natl Acad Sci U S A. 2020 Oct 21. pii: 2002997117.
    PubMed         Abstract available


    Radiology

  101. LANG K
    Mounting Evidence for Synthetic Mammography in Breast Cancer Screening.
    Radiology. 2020 Oct 13:203716. doi: 10.1148/radiol.2020203716.
    PubMed        

  102. KOSMIN M, Padhani AR, Gogbashian A, Woolf D, et al
    Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
    Radiology. 2020 Oct 20:192683. doi: 10.1148/radiol.2020192683.
    PubMed         Abstract available


    Radiother Oncol

  103. RATOSA I, Chirila ME, Steinacher M, Kozma E, et al
    Hypofractionated radiation therapy for breast cancer: preferences amongst radiation oncologists in europe - results from an international survey.
    Radiother Oncol. 2020 Oct 13. pii: S0167-8140(20)30844.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: